Swiss National Bank Has $10.24 Million Holdings in Insulet Co. (NASDAQ:PODD)

Share on StockTwits

Swiss National Bank raised its stake in Insulet Co. (NASDAQ:PODD) by 3.3% in the first quarter, HoldingsChannel.com reports. The fund owned 107,700 shares of the medical instruments supplier’s stock after purchasing an additional 3,400 shares during the period. Swiss National Bank’s holdings in Insulet were worth $10,241,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the business. Stephens Investment Management Group LLC increased its position in shares of Insulet by 19.6% in the first quarter. Stephens Investment Management Group LLC now owns 129,239 shares of the medical instruments supplier’s stock valued at $12,289,000 after buying an additional 21,206 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Insulet by 2.3% in the fourth quarter. California State Teachers Retirement System now owns 91,965 shares of the medical instruments supplier’s stock valued at $7,295,000 after buying an additional 2,073 shares in the last quarter. C WorldWide Group Holding A S increased its position in shares of Insulet by 102.6% in the first quarter. C WorldWide Group Holding A S now owns 52,672 shares of the medical instruments supplier’s stock valued at $5,009,000 after buying an additional 26,678 shares in the last quarter. Oak Ridge Investments LLC increased its position in shares of Insulet by 4.0% in the first quarter. Oak Ridge Investments LLC now owns 119,497 shares of the medical instruments supplier’s stock valued at $11,363,000 after buying an additional 4,648 shares in the last quarter. Finally, Standard Life Aberdeen plc purchased a new stake in shares of Insulet in the fourth quarter valued at approximately $16,011,000.

Shares of PODD opened at $115.85 on Thursday. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.71. Insulet Co. has a one year low of $70.80 and a one year high of $116.41. The company has a market cap of $6.55 billion, a P/E ratio of 2,317.00 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.05. Insulet had a return on equity of 7.01% and a net margin of 2.37%. The firm had revenue of $159.56 million during the quarter, compared to analysts’ expectations of $154.66 million. During the same period in the previous year, the business earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 29.1% on a year-over-year basis. As a group, equities analysts predict that Insulet Co. will post 0.27 EPS for the current year.

A number of research firms have recently commented on PODD. UBS Group boosted their price objective on Insulet to $130.00 and gave the company a “buy” rating in a research report on Thursday. Northland Securities cut Insulet from an “outperform” rating to a “market perform” rating and set a $100.00 price objective for the company. in a research report on Monday. BidaskClub upgraded Insulet from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Canaccord Genuity restated a “buy” rating and issued a $110.00 price objective (up from $100.00) on shares of Insulet in a research report on Monday, May 6th. Finally, BTIG Research upgraded Insulet from a “neutral” rating to a “buy” rating and set a $115.00 price target for the company in a research report on Monday, May 6th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $107.60.

In related news, Director John A. Fallon sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $100.00, for a total transaction of $500,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Charles Alpuche sold 3,900 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $104.78, for a total value of $408,642.00. The disclosure for this sale can be found here. Insiders have sold 54,289 shares of company stock valued at $5,725,737 over the last quarter. 3.50% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/4370262/swiss-national-bank-has-10-24-million-holdings-in-insulet-co-nasdaqpodd.html.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Read More: How accurate is the Rule of 72?

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Alliance Data Systems Co.  Receives Average Rating of “Hold” from Brokerages
Alliance Data Systems Co. Receives Average Rating of “Hold” from Brokerages
Host Hotels and Resorts Inc  Receives Consensus Recommendation of “Buy” from Analysts
Host Hotels and Resorts Inc Receives Consensus Recommendation of “Buy” from Analysts
Weir Group PLC  Given Consensus Rating of “Buy” by Analysts
Weir Group PLC Given Consensus Rating of “Buy” by Analysts
ViaSat, Inc.  Receives $96.99 Average Target Price from Analysts
ViaSat, Inc. Receives $96.99 Average Target Price from Analysts
Carrefour SA  Given Consensus Rating of “Hold” by Brokerages
Carrefour SA Given Consensus Rating of “Hold” by Brokerages
RTL Group S.A.  Receives €53.23 Consensus Target Price from Analysts
RTL Group S.A. Receives €53.23 Consensus Target Price from Analysts


© 2006-2019 Ticker Report